Abstract:BACKGROUND: Paclitaxel (PTX) is a first-line chemotherapeutic drug for the treatment of prostate cancer. However, most patients develop resistance and metastasis, and thus new therapeutic approaches are urgently required. Recent studies have identified widespread anti-tumor effects of zinc (Zn) in various tumor cell lines, especially prostate cancer cells. In this study, we examined the effects of Zn as an adjuvant to PTX in prostate cancer cells.METHODS: PC3 and DU145 cells were treated with different concentrations of Zn and/or PTX. MTT assay was used to detect cell viability. Real-time cell analysis (RTCA) and microscopy were used to observe morphological changes in cells. Western blotting was used to detect the expression of epithelial-mesenchymal transition (EMT)-related proteins. qPCR (reverse transcription-polymerase chain reaction) was used to examine changes in TWIST1 mRNA levels. Cell invasion and migration were detected by scratch and transwell assays. shRNA against TWIST1 was used to knockdown TWIST1. Colony formation assay was used to detect cell proliferation, while Annexin V and propidium iodide (PI) staining was used to detect cell apoptosis.RESULTS: Zn and PTX increased proliferation inhibition in a dose- and time-dependent manner in prostate cancer cells, while Zn increased prostate cancer cell chemosensitivity to PTX. Combined Zn and PTX inhibited prostate cancer cell invasion and migration by downregulating the expression of TWIST1. Furthermore, knockdown of TWIST1 increased the sensitivity of prostate cancer cells to PTX. In addition, Zn and PTX reduced cell proliferation and induced apoptosis in prostate cancer cells.CONCLUSIONS: Our results demonstrated that Zn and PTX combined therapy inhibits EMT by reducing the expression of TWIST1, which reduces the invasion and migration of prostate cancer cells. SiTWIST1 increased the sensitivity of prostate cancer cells to PTX. In addition, with prolonged treatment, Zn and PTX inhibited proliferation and led to prostate cancer cell apoptosis. Therefore, Zn may be a potential adjuvant of PTX in treating prostate cancer and combined treatment may offer a promising therapeutic strategy for prostate cancer.

Zeb1 Promotes Androgen Independence of Prostate Cancer Via Induction of Stem Cell-Like Properties.

Antiandrogen Treatment Induces Stromal Cell Reprogramming to Promote Castration Resistance in Prostate Cancer

Nkx3.1 and P27kip1cooperate in Proliferation Inhibition and Apoptosis Induction in Human Androgen–Independent Prostate Cancer Cells

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Identification of a Zeb1 Expressing Basal Stem Cell Subpopulation in the Prostate

Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer

Identification of a basal stem cell subpopulation in the prostate via functional, lineage tracing and single-cell RNA-seq analyses

Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.

Supplementary Figure 1 from Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy

PC-1/PrLZ Contributes to Malignant Progression in Prostate Cancer.

Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis

Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer

Increased Prlz-Mediated Androgen Receptor Transactivation Promotes Prostate Cancer Growth At Castration-Resistant Stage

Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46

Zeb1-Induced Tumourigenesis Requires Senescence Inhibition Via Activation of Dkk1/Mutant P53/Mdm2/Ctbp and Repression of Macroh2a1

AR-regulated ZIC5 Contributes to the Aggressiveness of Prostate Cancer

ZEB1 potentiates chemoresistance in breast cancer stem cells by evading apoptosis

Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial‐mesenchymal transition and inducing apoptosis

p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer

Plzf Mediates The Pten/Akt/Foxo3a Signaling In Suppression Of Prostate Tumorigenesis